Perdigó has extensive experience in the development of drug delivery devices for different routes of administration, including inhalation (soft mist and dry powder), parenteral, and ophthalmic. These pharmaceutical products are at the heart of our mission, helping patients manage debilitating conditions such as chronic obstructive pulmonary disease (COPD), growth hormone deficiency, or dry eyes.
The specific challenges of this market include engineering excellent delivered dose uniformity (DDU)—and aerodynamic particle size distribution (APSD) consistency, in the case of inhalers—scaling to high volume production, usability requirements to help maintain adherence, meeting sustainability goals, and adapting to novel formulations, including biologics. Time to clinic (from early pharmacokinetics studies to the pivotal clinical trial) and time to market are also critical.
Complex generics, which require expert navigation of their IP landscape, play an increasing role in modern healthcare. On the other hand, connected drug delivery products have had little success to date despite their great potential, in part due to their higher cost.
"Perdigó has very strong device development capabilities and experience for inhalation and broader drug delivery medical devices. They are an excellent development partner."
Steven Dudley, Head of Development Invox Pharma
“Perdigó’s mechanical design team showed impressive skills, particularly around tolerance analysis. Our collaboration on Design for Manufacturing and Assembly (DfMA) was very productive as a result.”
Gabe German, Senior mechanical design engineer Phillips Medisize (a Molex company)
